{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T19:03:45Z","timestamp":1777143825245,"version":"3.51.4"},"reference-count":43,"publisher":"Pharmaceutical Society of Japan","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2022,1,1]]},"DOI":"10.1248\/bpb.b21-00608","type":"journal-article","created":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T22:09:51Z","timestamp":1640988591000},"page":"94-103","source":"Crossref","is-referenced-by-count":9,"title":["Radiosynthesis and &lt;i&gt;in Vivo&lt;\/i&gt; and &lt;i&gt;ex Vivo&lt;\/i&gt; Evaluation of Isomeric [&lt;sup&gt;11&lt;\/sup&gt;C]methoxy Analogs of Nimesulide as Brain Cyclooxygenase-2-Targeted Imaging Agents"],"prefix":"10.1248","volume":"45","author":[{"given":"Yumi","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University"},{"name":"Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuro","family":"Tago","sequence":"additional","affiliation":[{"name":"Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Toyohara","sequence":"additional","affiliation":[{"name":"Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Saito","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiko","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Frejborg E, Salo T, Salem A. Role of cyclooxygenase-2 in head and neck tumorigenesis. <i>Int. J. Mol. Sci.<\/i>, <b>21<\/b>, 9246 (2020).","DOI":"10.3390\/ijms21239246"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Sheng J, Sun H, Yu FB, Li B, Zhang Y, Zhu YT. The role of cyclooxygenase-2 in colorectal cancer. <i>Int. J. Med. Sci.<\/i>, <b>17<\/b>, 1095\u20131101 (2020).","DOI":"10.7150\/ijms.44439"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Tudor DV, B\u00e2ldea I, Lupu M, Kacso T, Kutasi E, Hop\u00e2rtean A, Stretea R, Filip AG. COX-2 as a potential biomarker and therapeutic target in melanoma. <i>Cancer Biol. Med.<\/i>, <b>17<\/b>, 20\u201331 (2020).","DOI":"10.20892\/j.issn.2095-3941.2019.0339"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Kumar A, Behl T, Jamwal S, Kaur I, Sood A, Kumar P. Exploring the molecular approach of COX and LOX in Alzheimer\u2019s and Parkinson\u2019s disorder. <i>Mol. Biol. Rep.<\/i>, <b>47<\/b>, 9895\u20139912 (2020).","DOI":"10.1007\/s11033-020-06033-x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Singh A, Tripathi P, Singh S. Neuroinflammatory responses in Parkinson\u2019s disease: relevance of ibuprofen in therapeutics. <i>Inflammopharmacology<\/i>, <b>29<\/b>, 5\u201314 (2021).","DOI":"10.1007\/s10787-020-00764-w"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) L\u00f3pez DE, Ballaz SJ. The role of brain cyclooxygenase-2 (Cox-2) beyond neuroinflammation: neuronal homeostasis in memory and anxiety. <i>Mol. Neurobiol.<\/i>, <b>57<\/b>, 5167\u20135176 (2020).","DOI":"10.1007\/s12035-020-02087-x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Tietz O, Marshall A, Wuest M, Wang M, Wuest F. Radiotracers for molecular imaging of cyclooxygenase-2 (COX-2) enzyme. <i>Curr. Med. Chem.<\/i>, <b>20<\/b>, 4350\u20134369 (2013).","DOI":"10.2174\/09298673113206660260"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Laube M, Kniess T, Pietzsch J. Radiolabeled COX-2 inhibitors for non-invasive visualization of COX-2 expression and activity\u2014a critical update. <i>Molecules<\/i>, <b>18<\/b>, 6311\u20136355 (2013).","DOI":"10.3390\/molecules18066311"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Pacelli A, Greenman J, Cawthorne C, Smith G. Imaging COX-2 expression in cancer using PET\/SPECT radioligands: current status and future directions. <i>J. Labelled Comp. Radiopharm.<\/i>, <b>57<\/b>, 317\u2013322 (2014).","DOI":"10.1002\/jlcr.3160"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Janssen B, Mach RH. Development of brain PET imaging agents: Strategies for imaging neuroinflammation in Alzheimer\u2019s disease. <i>Prog. Mol. Biol. Transl. Sci.<\/i>, <b>165<\/b>, 371\u2013399 (2019).","DOI":"10.1016\/bs.pmbts.2019.04.005"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Meyer JH, Cervenka S, Kim MJ, Kreisl WC, Henter ID, Innis RB. Neuroinflammation in psychiatric disorders: PET imaging and promising new targets. <i>Lancet Psychiatry<\/i>, <b>7<\/b>, 1064\u20131074 (2020).","DOI":"10.1016\/S2215-0366(20)30255-8"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Kim MJ, Shrestha SS, Cortes M, Singh P, Morse C, Liow JS, Gladding RL, Brouwer C, Henry K, Gallagher E, Tye GL, Zoghbi SS, Fujita M, Pike VW, Innis RB. Evaluation of two potent and selective PET radioligands to image COX-1 and COX-2 in rhesus monkeys. <i>J. Nucl. Med.<\/i>, <b>59<\/b>, 1907\u20131912 (2018).","DOI":"10.2967\/jnumed.118.211144"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Shrestha S, Kim MJ, Eldridge M, <i>et al.<\/i> PET measurement of cyclooxygenase-2 using a novel radioligand: upregulation in primate neuroinflammation and first-in-human study. <i>J. Neuroinflammation<\/i>, <b>17<\/b>, 140 (2020).","DOI":"10.1186\/s12974-020-01804-6"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Caiazzo E, Ialenti A, Cicala C. The relatively selective cyclooxygenase-2 inhibitor nimesulide: what\u2019s going on? <i>Eur. J. Pharmacol.<\/i>, <b>848<\/b>, 105\u2013111 (2019).","DOI":"10.1016\/j.ejphar.2019.01.044"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Suleyman H, Cadirci E, Albayrak A, Halici Z. Nimesulide is a selective COX-2 inhibitory, atypical non-steroidal anti-inflammatory drug. <i>Curr. Med. Chem.<\/i>, <b>15<\/b>, 278\u2013283 (2008).","DOI":"10.2174\/092986708783497247"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Candelario-Jalil E. Nimesulide as a promising neuroprotectant in brain ischemia: new experimental evidences. <i>Pharmacol. Res.<\/i>, <b>57<\/b>, 266\u2013273 (2008).","DOI":"10.1016\/j.phrs.2008.03.003"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Catarro M, Serrano JL, Ramos SS, Silvestre S, Almeida P. Nimesulide analogues: from anti-inflammatory to antitumor agents. <i>Bioorg. Chem.<\/i>, <b>88<\/b>, 102966 (2019).","DOI":"10.1016\/j.bioorg.2019.102966"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Yamamoto Y, Hisa T, Arai J, Saito Y, Yamamoto F, Mukai T, Ohshima T, Maeda M, Ohkubo Y. Isomeric methoxy analogs of nimesulide for development of brain cyclooxygense-2 (COX-2)-targeted imaging agents: synthesis, <i>in vitro<\/i> COX-2-inhibitory potency, and cellular transport properties. <i>Bioorg. Med. Chem.<\/i>, <b>23<\/b>, 6807\u20136814 (2015).","DOI":"10.1016\/j.bmc.2015.10.007"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Yamamoto Y, Arai J, Hisa T, Saito Y, Mukai T, Ohshima T, Maeda M, Yamamoto F. Isomeric iodinated analogs of nimesulide: synthesis, physicochemical characterization, cyclooxygenase-2 inhibitory activity, and transport across Caco-2 cells. <i>Bioorg. Med. Chem.<\/i>, <b>24<\/b>, 3727\u20133733 (2016).","DOI":"10.1016\/j.bmc.2016.06.015"},{"key":"20","unstructured":"20) Vago T, Bevilacqua M, Norbiato G. Effect of nimesulide action time dependence on selectivity towards prostaglandin G\/H synthase\/cyclooxygenase activity. <i>Arzneimittelforschung<\/i>, <b>45<\/b>, 1096\u20131098 (1995)."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Yamamoto Y, Toyohara J, Ishiwata K, Sano K, Yamamoto F, Mukai T, Maeda M. <sup>11<\/sup>C-labeled analogs of indomethacin esters and amides for brain cyclooxygenase-2 imaging: Radiosynthesis, <i>in vitro<\/i> evaluation and <i>in vivo<\/i> characteristics in mice. <i>Chem. Pharm. Bull.<\/i>, <b>59<\/b>, 938\u2013946 (2011).","DOI":"10.1248\/cpb.59.938"},{"key":"22","unstructured":"22) Kimura M, Yamamoto F, Onishi I, Makino A, Yamamoto Y, Saito Y, Ozeki E, Kimura S, Ohkubo Y. <i>In vivo<\/i> evaluation of <sup>125<\/sup>I-labeled A<sub>3<\/sub>B lactosome with inflammatory model mice. <i>Kaku Igaku<\/i>, <b>50<\/b>, S250 (2013)."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Ishii K, Kikuchi Y, Matsuyama S, Kanai Y, Kotani K, Ito T, Yamazaki H, Funaki Y, Iwata R, Itoh M, Yanai K, Hatazawa J, Itoh N, Tanizaki N, Amano D, Yamada M, Yamaguchi T. First achievement of less than 1\u2009mm FWHM resolution in practical semiconductor animal PET scanner. <i>Nucl. Instrum. Methods Phys. Res. A<\/i>, <b>576<\/b>, 435\u2013440 (2007).","DOI":"10.1016\/j.nima.2007.03.018"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Okada K, Yamashita U, Tsuji S. Cyclooxygenase system contributes to the maintenance of post convulsive period of epileptic phenomena in the genetically epileptic el mice. <i>J. UOEH<\/i>, <b>28<\/b>, 265\u2013275 (2006).","DOI":"10.7888\/juoeh.28.265"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) de Vries EFJ, Doorduin J, Dierckx RA, van Waarde A. Evaluation of [<sup>11<\/sup>C]rofecoxib as PET tracer for cyclooxygenase 2 overexpression in rat models of inflammation. <i>Nucl. Med. Biol.<\/i>, <b>35<\/b>, 35\u201342 (2008).","DOI":"10.1016\/j.nucmedbio.2007.07.015"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Erfani M, Sharifzadeh S, Doroudi A, Shafiei M. Labeling and evaluation of <sup>99m<\/sup>Tc-tricarbonyl-meloxicam as a preferential COX-2 inhibitor for inflammation imaging. <i>J. Labelled Comp. Radiopharm.<\/i>, <b>59<\/b>, 284\u2013290 (2016).","DOI":"10.1002\/jlcr.3396"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Breder CD, Dewitt D, Kraig RP. Characterization of inducible cyclooxygenase in rat brain. <i>J. Comp. Neurol.<\/i>, <b>355<\/b>, 296\u2013315 (1995).","DOI":"10.1002\/cne.903550208"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Yamagata K, Andreasson KI, Kaufmann WE, Barnes CA, Worley PF. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. <i>Neuron<\/i>, <b>11<\/b>, 371\u2013386 (1993).","DOI":"10.1016\/0896-6273(93)90192-T"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Yoshikawa K, Takei S, Hasegawa-Ishii S, Chiba Y, Furukawa A, Kawamura N, Hosokawa M, Woodward DF, Watanabe K, Shimada A. Preferential localization of prostamide\/prostaglandin F synthase in myelin sheaths of the central nervous system. <i>Brain Res.<\/i>, <b>1367<\/b>, 22\u201332 (2011).","DOI":"10.1016\/j.brainres.2010.10.019"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) K\u00fc\u00e7\u00fckg\u00fczel SG, K\u00fc\u00e7\u00fckg\u00fczel I, Oral B, Sezen S, Rollas S. Detection of nimesulide metabolites in rat plasma and hepatic subcellular fractions by HPLC-UV\/DAD and LC-MS\/MS studies. <i>Eur. J. Drug Metab. Pharmacokinet.<\/i>, <b>30<\/b>, 127\u2013134 (2005).","DOI":"10.1007\/BF03226418"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Carini M, Aldini G, Stefani R, Marinello C, Facino RM. Mass spectrometric characterization and HPLC determination of the main urinary metabolites of nimesulide in man. <i>J. Pharm. Biomed. Anal.<\/i>, <b>18<\/b>, 201\u2013211 (1998).","DOI":"10.1016\/S0731-7085(98)00172-1"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Pandya KK, Satia MC, Modi IA, Modi RI, Chakravarthy BK, Gandhi TP. High-performance thin-layer chromatography for the determination of nimesulide in human plasma, and its use in pharmacokinetic studies. <i>J. Pharm. Pharmacol.<\/i>, <b>49<\/b>, 773\u2013776 (1997).","DOI":"10.1111\/j.2042-7158.1997.tb06110.x"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Rainsford K. The discovery, development and novel actions of nimesulide. <i>Nimesulide\u2014Actions and Uses<\/i>. (Rainsford K, ed.) Birkh\u00e4user, Basel, pp. 1\u201349 (2005).","DOI":"10.1007\/3-7643-7410-1_1"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Rainsford KD. Current status of the therapeutic uses and actions of the preferential cyclo-oxygenase-2 NSAID, nimesulide. <i>Inflammopharmacology<\/i>, <b>14<\/b>, 120\u2013137 (2006).","DOI":"10.1007\/s10787-006-1505-9"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Li F, Chordia MD, Huang T, Macdonald TL. <i>In vitro<\/i> nimesulide studies toward understanding idiosyncratic hepatotoxicity: diiminoquinone formation and conjugation. <i>Chem. Res. Toxicol.<\/i>, <b>22<\/b>, 72\u201380 (2009).","DOI":"10.1021\/tx800152r"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Kuban W, Daniel WA. Cytochrome P450 expression and regulation in the brain. <i>Drug Metab. Rev.<\/i>, <b>53<\/b>, 1\u201329 (2021).","DOI":"10.1080\/03602532.2020.1858856"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Hedlund E, Gustafsson JA, Warner M. Cytochrome P450 in the brain; a review. <i>Curr. Drug Metab.<\/i>, <b>2<\/b>, 245\u2013263 (2001).","DOI":"10.2174\/1389200013338513"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Miksys S, Tyndale RF. Cytochrome P450-mediated drug metabolism in the brain. <i>J. Psychiatry Neurosci.<\/i>, <b>38<\/b>, 152\u2013163 (2013).","DOI":"10.1503\/jpn.120133"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Macpherson D, Best SA, Gedik L, Hewson AT, Rainsford KD, Parisi S. The biotransformation and pharmacokinetics of 14C-Nimesulide in humans following a single dose oral administration. <i>J. Drug Metab. Toxicol.<\/i>, <b>4<\/b>, 1\u201313 (2012).","DOI":"10.4172\/2157-7609.1000140"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Sanad MH, Fouzy ASM, Sobhy HM, Hathout AS, Hussain OA. Tracing the protective activity of <i>Lactobacillus plantarum<\/i> using technetium-<sup>99m<\/sup>-labeled zearalenone for organ toxicity. <i>Int. J. Radiat. Biol.<\/i>, <b>94<\/b>, 1151\u20131158 (2018).","DOI":"10.1080\/09553002.2019.1524990"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Allott L, Brickute D, Chen C, Braga M, Barnes C, Wang N, Aboagye EO. Development of a fluorine-18 radiolabelled fluorescent chalcone: evaluated for detecting glycogen. <i>EJNMMI. Radiopharm. Chem.<\/i>, <b>5<\/b>, 17 (2020).","DOI":"10.1186\/s41181-020-00098-6"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Elsinga PH, Hendrikse NH, Bart J, Vaalburg W, van Waarde A. PET Studies on <i>P<\/i>-glycoprotein function in the blood\u2013brain barrier: how it affects uptake and binding of drugs within the CNS. <i>Curr. Pharm. Des.<\/i>, <b>10<\/b>, 1493\u20131503 (2004).","DOI":"10.2174\/1381612043384736"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Abdullahi W, Davis TP, Ronaldson PT. Functional expression of <i>P<\/i>-glycoprotein and organic anion transporting polypeptides at the blood\u2013brain barrier: understanding transport mechanisms for improved CNS drug delivery? <i>AAPS J.<\/i>, <b>19<\/b>, 931\u2013939 (2017).","DOI":"10.1208\/s12248-017-0081-9"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/45\/1\/45_b21-00608\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T04:35:01Z","timestamp":1715142901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/45\/1\/45_b21-00608\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b21-00608","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,1]]},"article-number":"b21-00608"}}